Precision Medicine with TGF-β Inhibition Using Tumor Explants: Comment on "Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor" by N. Sumru Bayin et al

Haidong Huang; Jennifer S Yu

doi:10.1016/j.neo.2016.10.009

Precision Medicine with TGF-β Inhibition Using Tumor Explants: Comment on "Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-β Small Molecule Inhibitor" by N. Sumru Bayin et al

Neoplasia. 2016 Dec;18(12):806-807. doi: 10.1016/j.neo.2016.10.009.

Authors

Haidong Huang¹, Jennifer S Yu²

Affiliations

¹ Department of Stem Cell Biology, Cleveland Clinic, Cleveland, OH, USA.
² Department of Stem Cell Biology, Cleveland Clinic, Cleveland, OH, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: yuj2@ccf.org.

Abstract

In a new report, Bayin et al. described an ex vivo explant model to test the patient-specific response to transforming growth factor-β inhibition in high-grade gliomas.

Publication types

Comment

MeSH terms

Brain Neoplasms
Glioma
Humans
Precision Medicine*
Receptors, Transforming Growth Factor beta
Signal Transduction / drug effects
Transforming Growth Factor beta*

Substances

Receptors, Transforming Growth Factor beta
Transforming Growth Factor beta